J&J Q1 Profit Beats

2026-07-15

J&J Quarterly Earnings Beat Wall Street Estimates on Strength of Medicines Unit

Johnson & Johnson beat Q2 sales and profit estimates, driven by strong growth in key drugs like Tremfya and Darzalex. It raised its full-year forecast despite challenges in its medical technology unit

reuters · 2026-07-15 03:23 UTC

2026-06-05

J&J Wins Lawsuit Alleging Talc Caused Three Women's Cancer

A Los Angeles jury ruled in favor of Johnson & Johnson in a lawsuit claiming its talc products caused ovarian cancer. J&J faces over 67,000 similar suits but halted U.S. talc-based baby powder sales i

reuters · 2026-06-05 15:24 UTC

2026-04-14

Johnson & Johnson First-Quarter Profit Beats Estimates Despite Stelara Sales Decline

Johnson & Johnson beat first-quarter earnings estimates with $24.1 billion revenue, raising its full-year forecast despite a 60% drop in Stelara sales due to biosimilar competition. Growth in cancer a

reuters · 2026-04-14 03:25 UTC

Media coverage (3)

J&J Quarterly Earnings Beat Wall Street Estimates on Strength of Medicines Unitreuters
J&J Wins Lawsuit Alleging Talc Caused Three Women's Cancerreuters
Johnson & Johnson First-Quarter Profit Beats Estimates Despite Stelara Sales Declinereuters

J&J Q1 Profit Beats

J&J Quarterly Earnings Beat Wall Street Estimates on Strength of Medicines Unit

J&J Wins Lawsuit Alleging Talc Caused Three Women's Cancer

Johnson & Johnson First-Quarter Profit Beats Estimates Despite Stelara Sales Decline

Media coverage (3)

Related topics